Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris
- PMID:24641090
- DOI: 10.1111/bjd.12706
Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris
Abstract
The time until a patient achieves a relevant improvement during the treatment of a skin disease is important for selecting a therapy, but has been largely neglected in reviews and guidelines. The aim of this systematic review was to determine the time until the onset of action (TOA) of topical acne treatments. The primary outcome was the TOA defined as the time until a 25% reduction in the mean number of inflammatory lesions had been achieved. A systematic literature search in Medline and Embase was carried out. Clinical trials that evaluated head-to-head comparisons of treatments in patients suffering from mild-to-moderate papulopustular acne were included. Abstract and full-text screening and data extraction were done independently by two investigators. With respect to inflammatory lesions, different concentrations of benzoyl peroxide (BPO) or adapalene did not seem to influence the TOA. BPO seemed to act more quickly than isotretinoin and tretinoin. Adapalene showed a shorter TOA than isotretinoin. Conflicting results were seen when comparing adapalene with tretinoin, with a tendency for adapalene to be faster. Clindamycin/BPO seemed to act more quickly than adapalene. Inconsistent results were seen for the comparison of clindamycin/BPO and BPO alone with a slight indication of a shorter TOA for clindamycin/BPO. Adapalene/BPO and clindamycin/BPO showed comparable TOA. When interpreting the data, the different study designs and the limited study quality need to be taken into account. Further research is needed to identify treatments that offer an early onset of action and possibly help to optimize patients' adherence. TOA should be considered as an additional outcome in acne trials.
Similar articles
- A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.Langner A, Chu A, Goulden V, Ambroziak M.Langner A, et al.Br J Dermatol. 2008 Jan;158(1):122-9. doi: 10.1111/j.1365-2133.2007.08308.x. Epub 2007 Nov 28.Br J Dermatol. 2008.PMID:18047518Clinical Trial.
- The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial.Babaeinejad SH, Fouladi RF.Babaeinejad SH, et al.J Drugs Dermatol. 2013 Jul 1;12(7):790-4.J Drugs Dermatol. 2013.PMID:23884492Clinical Trial.
- The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial.Babaeinejad SH, Fouladi RF.Babaeinejad SH, et al.J Drugs Dermatol. 2013 Sep;12(9):1033-8.J Drugs Dermatol. 2013.PMID:24002152Clinical Trial.
- Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years.Keating GM.Keating GM.Am J Clin Dermatol. 2011 Dec 1;12(6):407-20. doi: 10.2165/11208170-000000000-00000.Am J Clin Dermatol. 2011.PMID:21967116Review.
- Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis.Stuart B, Maund E, Wilcox C, Sridharan K, Sivaramakrishnan G, Regas C, Newell D, Soulsby I, Tang KF, Finlay AY, Bucher HC, Little P, Layton AM, Santer M.Stuart B, et al.Br J Dermatol. 2021 Sep;185(3):512-525. doi: 10.1111/bjd.20080. Epub 2021 Jun 16.Br J Dermatol. 2021.PMID:33825196Review.
Cited by
- Management of acne: Canadian clinical practice guideline.Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, Poulin Y, Shear NH, Tan J, Toole J, Zip C.Asai Y, et al.CMAJ. 2016 Feb 2;188(2):118-126. doi: 10.1503/cmaj.140665. Epub 2015 Nov 16.CMAJ. 2016.PMID:26573753Free PMC article.No abstract available.
- Topical, Biological and Clinical Challenges in the Management of Patients with Acne Vulgaris.Al-Hammadi A, Al-Ismaily A, Al-Ali S, Ramadurai R, Jain R, McKinley-Grant L, Mughal TI.Al-Hammadi A, et al.Sultan Qaboos Univ Med J. 2016 May;16(2):e152-60. doi: 10.18295/squmj.2016.16.02.004. Epub 2016 May 15.Sultan Qaboos Univ Med J. 2016.PMID:27226905Free PMC article.Review.
- Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials.Thiboutot DM, Kircik L, McMichael A, Cook-Bolden FE, Tyring SK, Berk DR, Chang-Lin JE, Lin V, Kaoukhov A.Thiboutot DM, et al.J Clin Aesthet Dermatol. 2016 Oct;9(10):18-27. Epub 2016 Oct 1.J Clin Aesthet Dermatol. 2016.PMID:27847545Free PMC article.
- Efficacy and Safety of a Fixed-Dose Combination Gel with Adapalene 0.1% and Clindamycin 1% for the Treatment of Acne Vulgaris (CACTUS): A Randomized, Controlled, Assessor-Blind, Phase III Clinical Trial.Luan C, Yang WL, Yin JW, Deng LH, Chen B, Liu HW, Zhang SM, Han J, Liu ZJ, Dai XR, Yin QJ, Yu XH, Chen K, Gu H, Li BXY.Luan C, et al.Dermatol Ther (Heidelb). 2024 Nov;14(11):3097-3112. doi: 10.1007/s13555-024-01286-x. Epub 2024 Nov 1.Dermatol Ther (Heidelb). 2024.PMID:39487326Free PMC article.
- Efficacy, safety, and subject satisfaction of a specified skin care regimen to cleanse, medicate, moisturize, and protect the skin of patients under treatment for acne vulgaris.Del Rosso JQ, Gold M, Rueda MJ, Brandt S, Winkelman WJ.Del Rosso JQ, et al.J Clin Aesthet Dermatol. 2015 Jan;8(1):22-30.J Clin Aesthet Dermatol. 2015.PMID:25610521Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical